What is Monobind?
Founded in 1978 and headquartered in Costa Mesa, California, Monobind has evolved into a premier manufacturer of immunoassays and diagnostic tools. With a track record of producing over 200 million units, the firm serves a diverse clientele ranging from biomedical researchers to international distributors across 30 countries. As a privately held entity, Monobind leverages its deep R&D authority to maintain a competitive edge, consistently delivering high-quality, cost-effective diagnostic solutions that meet rigorous international standards. The company's market position is defined by its longevity and its ability to integrate complex biological raw materials into scalable, reliable diagnostic products.
How much funding has Monobind raised?
Monobind has raised a total of $898K across 2 funding rounds:
Debt
$350K
Debt
$548K
Debt (2020): $350K with participation from PPP
Debt (2021): $548K led by PPP
Key Investors in Monobind
PPP
Public-Private Partnership
What's next for Monobind?
Looking ahead, the recent capital injection is expected to accelerate Monobind's strategic initiatives in diagnostic innovation and global market penetration. By utilizing this financing to optimize its supply chain and expand its R&D infrastructure, the company is well-positioned to address the increasing demand for precision diagnostics. As the healthcare landscape shifts toward more personalized and rapid testing solutions, Monobind's focus on maintaining its manufacturing excellence will be critical. The firm is likely to prioritize the development of next-generation assays, ensuring that its product portfolio remains at the forefront of clinical utility and diagnostic accuracy in an increasingly competitive global environment.
See full Monobind company page
